Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) and OnKure Therapeutics (NASDAQ:OKUR – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, valuation and risk.
Risk and Volatility
Agios Pharmaceuticals has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Comparatively, OnKure Therapeutics has a beta of 0.36, indicating that its stock price is 64% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Agios Pharmaceuticals and OnKure Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Agios Pharmaceuticals | 1 | 4 | 6 | 0 | 2.45 |
| OnKure Therapeutics | 1 | 2 | 1 | 0 | 2.00 |
Valuation & Earnings
This table compares Agios Pharmaceuticals and OnKure Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Agios Pharmaceuticals | $54.03 million | 31.01 | -$412.78 million | ($7.25) | -3.89 |
| OnKure Therapeutics | N/A | N/A | -$59.52 million | ($4.33) | -0.73 |
OnKure Therapeutics has lower revenue, but higher earnings than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Agios Pharmaceuticals and OnKure Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Agios Pharmaceuticals | -639.84% | -34.11% | -31.66% |
| OnKure Therapeutics | N/A | -61.02% | -55.99% |
Insider & Institutional Ownership
91.0% of OnKure Therapeutics shares are owned by institutional investors. 5.4% of Agios Pharmaceuticals shares are owned by company insiders. Comparatively, 2.3% of OnKure Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Agios Pharmaceuticals beats OnKure Therapeutics on 7 of the 13 factors compared between the two stocks.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
About OnKure Therapeutics
OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
